Comparing Interpace Diagnostics Group (IDXG) and its Peers
Interpace Diagnostics Group (NASDAQ: IDXG) is one of 98 publicly-traded companies in the “Business Support Services” industry, but how does it contrast to its rivals? We will compare Interpace Diagnostics Group to similar companies based off the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation.
This table compares Interpace Diagnostics Group and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-37.08%||-32.06%||-11.22%|
|Interpace Diagnostics Group Competitors||-129.07%||-181.06%||-5.92%|
Institutional & Insider Ownership
7.6% of Interpace Diagnostics Group shares are held by institutional investors. Comparatively, 63.0% of shares of all “Business Support Services” companies are held by institutional investors. 0.7% of Interpace Diagnostics Group shares are held by company insiders. Comparatively, 11.9% of shares of all “Business Support Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Interpace Diagnostics Group and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||1||0||3.00|
|Interpace Diagnostics Group Competitors||731||2076||2662||84||2.38|
Interpace Diagnostics Group currently has a consensus price target of $5.00, suggesting a potential upside of 208.64%. All “Business Support Services” companies have a potential downside of 4.55%. Given Interpace Diagnostics Group’s stronger consensus rating and higher possible upside, research analysts plainly believe Interpace Diagnostics Group is more favorable than its rivals.
Valuation & Earnings
This table compares Interpace Diagnostics Group and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Interpace Diagnostics Group||$13.76 million||-$10.89 million||-1.69|
|Interpace Diagnostics Group Competitors||$1.11 billion||$177.91 million||-15,154.33|
Interpace Diagnostics Group’s rivals have higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently the more expensive than other companies in its industry.
Volatility and Risk
Interpace Diagnostics Group has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Interpace Diagnostics Group’s rivals have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.